Edwards' Transcatheter Tricuspid Replacement System Shows Favorable Patient Outcomes

Edwards Lifesciences Corporation EW announced results from the TRISCEND study of its EVOQUE transcatheter tricuspid valve replacement system.
Patients enrolled in the TRISCEND study had symptomatic, moderate, or greater functional or degenerative tricuspid regurgitation (TR), despite optimal medical therapy.
The 6-month results (n=56) demonstrated significant TR reduction by core laboratory assessment.
A significant reduction in TR severity was observed, with 100% of patients with none/trace or mild TR in 43 patients with paired echocardiographic data available.
Significantly improved functional and quality-of-life outcomes were seen.
Data showed a survival rate of 96% and freedom from heart failure hospitalization rate of 94%.
The EVOQUE valve replacement system is an investigational device and is not available for sale in any country.
Price Action: EW shares closed at $118.65 on Friday.